Nexalin Technology is a non-invasive and drug-free therapy for those living with anxiety, depression and/or insomnia. Nexalin’s Patented Waveform (1 U.S. Patent #6904322B2) The Nexalin device produces a patented waveform that provides Transcranial Electrical Stimulation (TES). In clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. The Nexalin device has undergone extensive safety analysis with the results clearly indicating that the device is safe for its intended use. Additionally, the FDA classification of the device for clinical trials places it into a non-significant risk (low risk device) category. Natural frequency will promote balance in the brain by normalizing neurochemistry.This effectiveness of this unique therapy is long lasting and FDA approved. Laboratory and clinical evidence suggest that Nexalin’s patented electrical stimulation affects the hypothalamus and related brain structures to adapt and change the levels of neurochemicals including neuropeptides, neurotransmitters, and neuromodulators. The clinical data suggests that the Nexalin electrical stimulation will move endocrine outputs toward normalization, specifically from the hypothalamic nuclei and associated brain structures. A key indicator of this is a significant clinical change in levels of enkephalins and beta-endorphins in the cerebral spinal fluid of Nexalin-treated subjects, as well as other neurochemicals like Serotonin and Dopamine.